Table 1.
Clinical characteristics of patients
| Characteristic | n (%) |
| Total | 90 (100.0) |
| Gender (M/F) | 59 (65.6)/31 (34.4) |
| Median age (yr) | 48 (range: 16-71) |
| Underlying disease | |
| Multiple myeloma | 46 (51.1) |
| Hodgkin’s lymphoma | 23 (25.6) |
| Non-Hodgkin’s lymphoma | 15 (4.4) |
| Acute myeloblastic leukemia | 4 (4.4) |
| Acute lymphoblastic leukemia | 1 (1.1) |
| Primitive neuroectodermal tumor | 1 (1.1) |
| Conditioning regimen | |
| Melphalan | 47 (52.2) |
| BEAM | 35 (38.9) |
| Busulfex-Cy | 4 (4.4) |
| Busulfex-Melphalan | 1 (1.1) |
| TBI-Cy-Thiotepa | 1 (1.1) |
| Thiotepa-Cy-Bu | 1 (1.1) |
| Z-BEAM | 1 (1.1) |
BEAM: The combination of Carmustine (BCNU), Etoposide, Cytarabine (Ara-C) and Melphalan; Z-BEAM: The combination of Ybritumomab Tiuxetan (Zevalin®), Carmustine (BCNU), Etoposide, Cytarabine (Ara-C) and Melphalan; Cy: Cyclophosphamide; TBI: Total body irradiation.